Copertina

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Mathieu Uzzan, David Laharie, Julien Kirchgesner
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
di: Shintaro Akiyama, et al.
Pubblicazione: (2025)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
di: Mathilde Osty, et al.
Pubblicazione: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
di: Nathan Grellier, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
di: Bharati Kochar, et al.
Pubblicazione: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
di: Cristina Rubín de Célix, et al.
Pubblicazione: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
di: Aurelien Amiot, et al.
Pubblicazione: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
di: Isabel Carbery, et al.
Pubblicazione: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
di: Sanjay K. Murthy
Pubblicazione: (2026)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
di: Monica E. W. Derks, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively?
di: David Laharie
Pubblicazione: (2024)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
di: Anupam Kumar Singh, et al.
Pubblicazione: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease
di: Jeli Mendoza, et al.
Pubblicazione: (2024)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
di: Matthew D. Coates, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
di: Marco Vincenzo Lenti, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
di: Agnes Hiu Yan Ho, et al.
Pubblicazione: (2025)

Early ileal resection in Crohn's disease is not associated with severe long‐term outcomes: The ERIC study
di: Nathan Grellier, et al.
Pubblicazione: (2024)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
di: Stephanie Gold, et al.
Pubblicazione: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
di: Nicholas Clark, et al.
Pubblicazione: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
di: Joyce Wing Yan Mak
Pubblicazione: (2025)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
di: Nicolas Richard, et al.
Pubblicazione: (2026)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
di: Purab Patel, et al.
Pubblicazione: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
di: Terry Cheuk‐Fung Yip, et al.
Pubblicazione: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
di: Jane Lim, et al.
Pubblicazione: (2025)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
di: Kee Huat Chuah, et al.
Pubblicazione: (2025)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
di: Uma Mahadevan, et al.
Pubblicazione: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
di: Quinn Goddard, et al.
Pubblicazione: (2025)

Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
di: Konstantinos Papamichael, et al.
Pubblicazione: (2024)